TECX

Tectonic Therapeutic Inc

21.97

Nov 10 • 3:59 PM ET +0.08 (0.37%)

21.97

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: GPCR SEPN BRVE KARD CYTK RNA EWTX MLYS ATTO TNYA

| Held by: VTI IWM VXF IWN IBB VTWO IWC VHT SBIO AVSC

Scroll to Statements

Index	RUT
Market Cap	438.26M
Enterprise Value	207.99M
Income	-88.10M
Sales	0.00M
Book/sh	11.64
Cash/sh	11.76
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	60
IPO	Jun 21, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.89
P/C	1.87
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	22.29
Current Ratio	22.29
Debt/Eq	0.02
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-4.63
EPS next Y	-5.31
EPS next Q	-1.38
EPS this Y	-22.23%
EPS next Y	-7.28%
EPS next 5Y	-14.44%
EPS past 3/5Y	48.16% 36.65%
Sales past 3/5Y	- -
EPS Y/Y TTM	-20.25%
Sales Y/Y TTM	-
EPS Q/Q	-6.51%
Sales Q/Q	-
Earnings	Nov 05 AMC
EPS/Sales Surpr.	17.95% -

Insider Own	48.00%
Insider Trans	-0.01%
Inst Own	55.41%
Inst Trans	-3.16%
ROA	-33.83%
ROE	-35.46%
ROIC	-38.87%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	6.60%
SMA50	-7.89%
SMA200	-21.88%
Trades

Shs Outstand	19.95M
Shs Float	10.37M
Short Float	22.91%
Short Ratio	10.70
Short Interest	2.38M
52W High	39.53 -44.42%
52W Low	16.77 31.01%
Volatility	7.56% 5.88%
ATR (14)	1.37
RSI (14)	52.01
Beta	1.24
Rel Volume	0.87
Avg Volume	222.03K
Volume	192,791

Perf Week	15.75%
Perf Month	-1.70%
Perf Quarter	-40.35%
Perf Half Y	-21.42%
Perf YTD	5.32%
Perf Year	16.37%
Perf 3Y	33.64%
Perf 5Y	-65.91%
Perf 10Y	-
Recom	1.20
Target Price	71.00
Prev Close	21.89
Price	21.97
Change %	0.37%

Consensus

Strong Buy

Avg. Price Target

$71.00

Implied Upside

+223.2%

Analysts14incl. previous ratings

Rating Distribution11 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 12, 2026	Initiated	UUBS	Neutral	$26	+18.3%
May 26, 2026	Upgrade	RRaymond James	Outperform → Strong Buy	$81	+268.7%
Apr 14, 2026	Initiated	SStifel	Buy	$75	+241.4%
Oct 20, 2025	Initiated	WWells Fargo	Overweight	$101	+359.7%
Sep 03, 2025	Initiated	OOppenheimer	Outperform	$80	+264.1%
Jul 21, 2025	Initiated	TTruist	Buy	$64	+191.3%
Jun 11, 2025	Resumed	RRaymond James	Outperform	$76	+245.9%
Apr 21, 2025	Initiated	MMizuho	Outperform	$51	+132.1%
Nov 20, 2024	Initiated	RRaymond James	Outperform	$65	+195.9%
Aug 22, 2024	Initiated	WWells Fargo	Overweight	$55	+150.3%
Jun 26, 2024	Initiated	PPiper Sandler	Overweight
Jun 24, 2024	Initiated	TTD Cowen	Buy
Dec 18, 2023	Downgrade	MMizuho	Buy → Neutral
Jan 05, 2022	Downgrade	BBTIG Research	Buy → Neutral
Nov 19, 2021	Downgrade	MMorgan Stanley	Overweight → Equal-Weight	$24 → $7	-68.1%
Jun 15, 2021	Initiated	BBTIG Research	Buy	$23	+4.7%
May 27, 2021	Initiated	NNeedham	Buy	$28	+27.4%
Mar 09, 2021	Initiated	BBarclays	Overweight	$23	+4.7%
Mar 02, 2021	Initiated	SStifel	Hold	$14	-36.3%
Nov 11, 2020	Initiated	BBerenberg	Buy

Nov-09-26 08:00AM	Tectonic Therapeutic to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.06%
Nov-05-26 04:01PM	Tectonic Therapeutic Announces Third Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) +6.28%
Sep-29-26 08:00AM	Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) (GlobeNewswire)
Sep-03-26 08:00AM	Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Aug-06-26 04:01PM	Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
04:01PM	Loading…
Jun-10-26 04:01PM	Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients (GlobeNewswire)
May-07-26 04:01PM	Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) -7.41% +7.93%
Apr-23-26 04:01PM	Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors (GlobeNewswire)
Mar-02-26 08:00AM	Tectonic Therapeutic to Participate in March Investor Conferences (GlobeNewswire)
Feb-26-26 04:17PM	Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-25-26 04:18AM	Tectonic Therapeutic Spotlights TX2100 in HHT as First-in-Human Phase 1 Dosing Begins (MarketBeat) +8.24%
Feb-23-26 04:01PM	Tectonic Therapeutic Appoints Francois Nader, M.D., as Chair and Independent Director of the Board (GlobeNewswire)
Feb-11-26 04:01PM	Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026 (GlobeNewswire)
Dec-10-25 02:13PM	Tectonic Therapeutic (TECX): LifeSci Capital Reiterates Buy Rating (Insider Monkey)
Dec-01-25 08:00AM	Tectonic Therapeutic to Participate in December Investor Conferences (GlobeNewswire)
04:01PM	Loading…
Nov-06-25 04:01PM	Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +15.51%
Oct-29-25 04:01PM	Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF (GlobeNewswire) -5.48%
Aug-28-25 09:00AM	Tectonic Therapeutic to Participate in September Investor Conferences (GlobeNewswire)
Aug-07-25 04:01PM	Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -5.35%
Jun-30-25 08:00AM	Tectonic Therapeutic Joins Russell 3000 Index (GlobeNewswire)
Jun-24-25 05:42PM	Raymond James Resumes Coverage of Tectonic Therapeutic (TECX) With an Outperform Rating (Insider Monkey) +7.57%
May-17-25 10:40AM	Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025 (GlobeNewswire)
May-13-25 09:55AM	Wall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High? (Zacks)
May-08-25 04:01PM	Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +10.81% -5.99%
May-07-25 08:00AM	Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference (GlobeNewswire)
May-01-25 05:59AM	TipRanks Perfect 10 Picks: 2 Top-Scoring Stocks Earning Wall Streets Seal of Approval (TipRanks) -5.75%
Apr-23-25 05:51AM	Tectonic Therapeutic: A Buy On Massive Opportunity Of TX45 In PH HFpEF (Seeking Alpha)
Apr-15-25 08:00AM	Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025 (GlobeNewswire)
Mar-20-25 04:01PM	Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-04-25 08:26PM	Is Tectonic Therapeutic, Inc. (TECX) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
08:00AM	Loading…
Feb-20-25 08:00AM	Tectonic Therapeutic to Participate in March Investor Conferences (GlobeNewswire)
Feb-03-25 06:30AM	Tectonic Announces $185 Million Private Placement (GlobeNewswire) -6.52%
Jan-30-25 06:30AM	Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF (GlobeNewswire) +113.22%
Dec-03-24 04:01PM	Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024 (GlobeNewswire)
Nov-26-24 04:01PM	Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-12-24 11:01PM	Tectonic Therapeutic Inc. Reports Q3 2024 Results (TipRanks)
Nov-11-24 05:00AM	Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein (GlobeNewswire)
Nov-07-24 04:01PM	Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-22-24 04:01PM	Tectonic Therapeutic to Present Phase 1a Data at AHA 2024 (GlobeNewswire)
Sep-19-24 04:01PM	Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45 (GlobeNewswire)
Aug-20-24 04:01PM	Tectonic Therapeutic to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-24 04:01PM	Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) +5.23%
Jul-30-24 04:01PM	Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45 (GlobeNewswire)
Jun-20-24 04:01PM	Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million (Business Wire)
09:47AM	PLTR Stock: Palantir Bags New Partnership With ARPA-H for AI/ML (InvestorPlace)
08:26AM	Why Is Avrobio (AVRO) Stock Moving Today? (InvestorPlace)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
May-15-24 11:27AM	Avrobio Insider Bought Shares Worth $971,493, According to a Recent SEC Filing (MT Newswires) +6.20%
May-13-24 09:53AM	AVRO Stock Earnings: Avrobio Beats EPS for Q1 2024 (InvestorPlace) +9.76%
Feb-27-24 10:50AM	Kuehn Law Encourages CHRD, AVRO, KAMN, and CTLT Investors to Contact Law Firm (PR Newswire)
Feb-01-24 02:25PM	Kuehn Law Encourages ICVX, CSTR, AVRO, and CALB Investors to Contact Law Firm (PR Newswire)
Jan-31-24 10:40AM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates TAST, AVRO, CALB (GlobeNewswire) +9.57%
06:42AM	Avrobios road ends in reverse merger with Tim Springer-backed startup (BioPharma Dive)
Jan-30-24 02:52PM	Avrobio's corporate tremor attracts Tectonic for reverse merger (FierceBiotech.com) -16.06%
02:38PM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AVRO, CALB, BCAL (PR Newswire)
08:00AM	AVROBIO and Tectonic Therapeutic Announce Merger (Business Wire)
Nov-08-23 09:40AM	Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-23-23 09:40AM	Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-06-23 09:40AM	Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year? (Zacks)
Jul-13-23 07:08AM	AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46% (Zacks)
Jul-12-23 07:00AM	AVROBIO to Explore Strategic Alternatives (Business Wire) +45.96%
Jun-12-23 07:00AM	AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million (Business Wire)
May-22-23 07:00AM	AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million (Business Wire) +69.01%
May-18-23 02:53PM	Avrobio Touts Positive Data Gene Therapy Trial For Cystinosis, Showing Treatment Durability Of Up To 36 Months (Benzinga) +45.33%
07:00AM	AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting (Business Wire)
May-11-23 07:00AM	AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
May-01-23 07:30AM	AVROBIO Announces Leadership Transition (Business Wire) -15.99%
Mar-23-23 07:00AM	AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update (Business Wire) -27.64%
Mar-03-23 07:00AM	AVROBIO to Participate in Cowens 43rd Annual Health Care Conference (Business Wire)
Feb-09-23 07:00AM	AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium 2023 (Business Wire) +7.69%
Jan-05-23 07:00AM	AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-07-22 07:30AM	AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy (Business Wire) -6.96%
Nov-17-22 07:00AM	AVROBIO to Share Comprehensive Gaucher Disease Program Update (Business Wire) +5.40%
Nov-08-22 07:00AM	AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Nov-07-22 07:00AM	AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit (Business Wire)
Nov-03-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-27-22 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease (Business Wire)
Oct-25-22 07:00AM	AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis (Business Wire)
Oct-18-22 07:00AM	AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease (Business Wire) +12.37%
Oct-11-22 07:00AM	AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development (Business Wire)
Oct-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-27-22 07:00AM	AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress (Business Wire) -10.23%
Sep-20-22 07:00AM	AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis (Business Wire)
Sep-14-22 07:28AM	AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial (Business Wire)
Sep-08-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-31-22 07:00AM	AVROBIO to Participate in Four Upcoming Investor Conferences in September (Business Wire)
Aug-09-22 07:00AM	AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update (Business Wire)
Aug-04-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-01-22 07:00AM	AVROBIO to Participate in Two Upcoming Investor Conferences in August (Business Wire)
Jul-13-22 07:00AM	AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome (Business Wire)
Jul-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.47%
May-18-22 03:12PM	AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study (Zacks) -8.57%
12:41PM	Avrobio's Pompe Disease Gene Therapy Shows Efficacy, Safety In Preclinical Study (Benzinga)
07:00AM	AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (Business Wire)
May-17-22 12:15PM	AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study (Benzinga)
07:00AM	AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures (Business Wire)
May-16-22 07:00AM	AVROBIO to Present at the H.C. Wainwright Global Investment Conference (Business Wire)
May-10-22 07:00AM	AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update (Business Wire)
May-06-22 07:00AM	AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-03-22 07:00AM	AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
REICIN ALISE	Chief Executive Officer	Oct 26 '26	Option Exercise	2.38	10,000	23,800	319,078	Oct 28 04:30 PM
McNamara Peter	Chief Scientific Officer	Sep 30 '26	Sale	23.04	536	12,349	54,305	Oct 02 05:00 PM
PETER MCNAMARA	Officer	Sep 30 '26	Proposed Sale	23.34	493	11,507		Sep 30 04:21 PM
TERRANCE MCGUIRE	Former Director	Aug 27 '26	Proposed Sale	36.83	7,513	276,718		Aug 27 05:20 PM
McNamara Peter	Chief Scientific Officer	Aug 25 '26	Option Exercise	14.71	43	633	55,328	Aug 26 04:30 PM
McNamara Peter	Chief Scientific Officer	Aug 25 '26	Sale	36.52	43	1,570	55,285	Aug 26 04:30 PM
TERRANCE MCGUIRE	Former Director	Aug 21 '26	Proposed Sale	37.61	10,200	383,671		Aug 21 05:58 PM
McNamara Peter	Chief Scientific Officer	Aug 12 '26	Option Exercise	14.71	43	633	55,328	Aug 14 07:25 PM
McNamara Peter	Chief Scientific Officer	Aug 12 '26	Sale	35.00	43	1,505	55,285	Aug 14 07:25 PM
PETER MCNAMARA	Officer	Aug 12 '26	Proposed Sale	31.87	129	4,111		Aug 12 04:37 PM
McNamara Peter	Chief Scientific Officer	Jun 30 '26	Option Exercise	14.71	172	2,530	55,457	Jul 01 05:19 PM
McNamara Peter	Chief Scientific Officer	Jun 30 '26	Sale	35.00	172	6,020	55,285	Jul 01 05:19 PM
PETER MCNAMARA	Officer	Jun 30 '26	Proposed Sale	33.09	172	5,691		Jun 30 04:38 PM
Ruddy Marcella K.	Chief Medical Officer	May 04 '26	Sale	30.00	1,065	31,950	67,682	May 06 05:00 PM
Ruddy Marcella K.	Chief Medical Officer	Apr 01 '26	Sale	31.05	1,000	31,050	68,747	Apr 03 04:24 PM
Ruddy Marcella K.	Chief Medical Officer	Mar 06 '26	Sale	30.00	10,000	300,000	69,747	Mar 09 06:15 PM
McNamara Peter	Chief Scientific Officer	Mar 06 '26	Option Exercise	3.36	2,715	9,113	61,547	Mar 09 06:12 PM
McNamara Peter	Chief Scientific Officer	Mar 06 '26	Sale	30.17	6,262	188,935	55,285	Mar 09 06:12 PM
PETER MCNAMARA	Officer	Mar 06 '26	Proposed Sale	27.85	6,262	174,397		Mar 06 04:31 PM
MARCELLA RUDDY	Officer	Mar 06 '26	Proposed Sale	27.85	12,065	336,010		Mar 06 04:31 PM
McNamara Peter	Chief Scientific Officer	Mar 04 '26	Sale	25.00	1,650	41,250	58,832	Mar 05 05:45 PM
McNamara Peter	Chief Scientific Officer	Mar 03 '26	Sale	22.06	1,649	36,377	37,482	Mar 05 05:45 PM
PETER MCNAMARA	Officer	Mar 04 '26	Proposed Sale	24.39	1,650	40,252		Mar 04 04:42 PM
PETER MCNAMARA	Officer	Mar 03 '26	Proposed Sale	23.00	1,649	37,927		Mar 03 04:44 PM
REICIN ALISE	Chief Executive Officer	Feb 11 '26	Buy	21.10	2,500	52,750	237,547	Feb 12 04:15 PM
Schwabish Marc	Chief Business Officer	Feb 10 '26	Option Exercise	2.38	4,500	10,710	25,814	Feb 12 04:15 PM
Lochner Daniel	Chief Financial Officer	Feb 10 '26	Buy	21.61	6,000	129,660	32,044	Feb 11 05:32 PM
REICIN ALISE	Chief Executive Officer	Dec 31 '25	Option Exercise	2.38	10,966	26,099	239,151	Jan 05 05:02 PM
McNamara Peter	Chief Scientific Officer	Dec 22 '25	Option Exercise	2.98	7,000	20,860	40,879	Dec 29 04:35 PM

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). It develops a proprietary technology platform called GEODe to enable the discovery and development of GPCR-targeted biologic medicines. The company was founded by Timothy A. Springer and Andrew Kruse in November 2015 and is headquartered in Watertown, MA.

Ph.D.Dr. Alise S. Reicin M.D.

Chief Financial OfficerMr. Daniel Lochner M.B.A.

M.S.Dr. Marcella Kuhlman Ruddy M.D.

Senior Vice President of Technical OperationsMr. Washington Alves M.S.

Chief Scientific OfficerDr. Peter McNamara Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TECX

Tectonic Therapeutic Inc

Upgrade your Finviz experience